Poonam A. Arora
Long/short equity, value, research analyst, biotech

Epizyme: Strong Early Data But Reserving Judgment Until Final Results

Investment Conclusion. Initial data read outs from the Epizyme (NASDAQ:EPZM) EPZ-6438 Phase I dose escalation study were robust. The drug showed early indications of activity in two NHL patients, there was a lack of significant dose limiting toxicities (DLTs), and maximum tolerated dose [MTD] was not reached. In addition, there were pharmacodynamic effects of methyl mark reduction observed in the skin. This means that EPZM is now free to give patients higher doses of the drug and for longer durations with lower immediate safety risk. Greater dose intensity and dose density might result in more tumor responses as well as stronger and possibly durable effects. In addition, higher doses given for more cycles, might lead to sufficient levels...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details